The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| XTNT | +1.91% | -65.93% | -19.37% | -100% |
| S&P | +14.43% | +77.25% | +12.13% | +576% |
Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoSTX, Certex Spinal Fixation System, Axle Interspinous Fusion System, and Calix. The company was founded in 2006 and is headquartered in Belgrade, MT.
No news articles found for Xtant Medical.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $33.26M | 19.0% |
| Gross Profit | $21.99M | 34.9% |
| Gross Margin | 66.13% | 7.8% |
| Market Cap | $84.56M | -9.8% |
| Market Cap / Employee | $364.49K | 0.0% |
| Employees | 232 | 0.0% |
| Net Income | $1.31M | 126.0% |
| EBITDA | $3.70M | 236.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $10.64M | 50.2% |
| Accounts Receivable | $25.52M | 24.2% |
| Inventory | 40.7 | -2.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $20.38M | 4.8% |
| Short Term Debt | $12.11M | -26.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 1.71% | 20.1% |
| Return On Invested Capital | -19.73% | 0.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $4.18M | 209.4% |
| Operating Free Cash Flow | $4.61M | 368.5% |
| Metric | Q3 2025 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 63.62 | - | |||
| Price to Book | 1.34 | 1.52 | 2.34 | 1.86 | -4.78% |
| Price to Sales | 0.53 | 0.55 | 0.86 | 0.73 | -8.59% |
| Price to Tangible Book Value | 2.07 | 2.39 | 3.59 | 2.68 | -13.29% |
| Price to Free Cash Flow TTM | 19.05 | - | |||
| Enterprise Value to EBITDA | -123.28 | 45.03 | 24.14 | 32.26 | -172.58% |
| Free Cash Flow Yield | 5.3% | - | |||
| Return on Equity | -34.9% | -26.2% | -9.8% | 3.6% | -110.40% |
| Total Debt | $35.14M | $34.30M | $37.07M | $32.49M | -9.63% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
